18 Nov 2022
The drug, tepluzimab, an anti-CD3 antibody, has now been approved by the U.S. Food and Drug Administration (FDA) for children and adults with preclinical type 1 diabetes. A 14-day intravenous course of teplizumab has been shown to be capable of slowing the course of onset of type 1 diabetes. Tepluzimab is not currently licensed in the UK and will need to be assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) before it becomes available.
References
Research Assistant in Endocrinology (University of Sheffield)
14 May 2024
BSPED Research and Innovation Award 2024 now open
03 May 2024
Nurse and Allied Health Professionals Award 2024 – applications now open
03 May 2024
Committee opportunity: Clinical Standards Officer
03 May 2024
Updated: UK Paediatric Endocrine Standards
03 May 2024